Onabotulinum toxin A treatment of cervicogenic headache: A randomised, double-blind, placebo-controlled crossover study

Cephalalgia

Volumn 31, Issue 7, 2011, Pages 797-807

  Linde, Mattias ^a,b   Hagen, Knut ^a,b   Salvesen, Øyvind ^a   Gravdahl, Gøril Bruvik ^b   Helde, Grethe ^a   Stovner, Lars Jacob ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Botulinum toxin A; cervicogenic headache; neck muscles; randomised controlled trial

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; MUSCLE RELAXANT AGENT;

ADULT; AGED; ALGOMETRY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERVENTILATION; INJECTION SITE PAIN; LACRIMATION; MALE; MUSCLE WEAKNESS; NAUSEA; NECK MUSCLE; PRESSURE PAIN THRESHOLD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SECONDARY HEADACHE; SHORT FORM 36; SIDE EFFECT; STIFF NECK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; JOINT CHARACTERISTICS AND FUNCTIONS; POSTTRAUMATIC HEADACHE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXINS, TYPE A; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NECK MUSCLES; NEUROMUSCULAR AGENTS; POST-TRAUMATIC HEADACHE; QUALITY OF LIFE; QUESTIONNAIRES; RANGE OF MOTION, ARTICULAR; TREATMENT OUTCOME;

EID: 80054120288     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102411398402     Document Type: Article

References (55)

1. Aaseth K Grande RB Kvaerner KJ Gulbrandsen P Lundqvist C Russell MB. Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. Cephalalgia 2008; 28: 705-713.
2. Sjaastad O Bakketeig LS. Prevalence of cervicogenic headache: Vaga study of headache epidemiology. Acta Neurol Scand 2008; 117: 173-180.
3. Nilsson N. The prevalence of cervicogenic headache in a random population sample of 20-59 year olds. Spine 1995; 20: 1884-1888.
4. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. Clin Exp Rheumatol 2000; 18 (2 Suppl 19): S59-S64.
5. Becker WJ. Cervicogenic headache: evidence that the neck is a pain generator. Headache 2010; 50: 699-705.
6. Evers S. Comparison of cervicogenic headache with migraine. Cephalalgia 2008; 28 (Suppl 1): 16-17.
7. Bogduk N Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959-968.
8. Becser N Sand T Pareja JA Zwart JA. Thermal sensitivity in unilateral headaches. Cephalalgia 1998; 18: 675-683. discussion 57.
9. Vincent MB. Cervicogenic headache: the neck is a generator: con. Headache 2010; 50: 706-709.
10. Jull G Barrett C Magee R Ho P. Further clinical clarification of the muscle dysfunction in cervical headache. Cephalalgia 1999; 19: 179-185.
11. Zito G Jull G Story I. Clinical tests of musculoskeletal dysfunction in the diagnosis of cervicogenic headache. Man Ther 2006; 11: 118-129.
12. Bansevicius D Sjaastad O. Cervicogenic headache: the influence of mental load on pain level and EMG of shoulder-neck and facial muscles. Headache 1996; 36: 372-378.
13. Boquet J Boismare F Payenneville G Leclerc D Monnier JC Moore N. Lateralization of headache: possible role of an upper cervical trigger point. Cephalalgia 1989; 9: 15-24.
14. Jaeger B. Are "cervicogenic" headaches due to myofascial pain and cervical spine dysfunction? Cephalalgia 1989; 9: 157-164.
15. Roth JK Roth RS Weintraub JR Simons DG. Cervicogenic headache caused by myofascial trigger points in the sternocleidomastoid: a case report. Cephalalgia 2007; 27: 375-380.
16. Fernandez-de-Las-Penas C Cuadrado ML Pareja JA. Myofascial trigger points, neck mobility and forward head posture in unilateral migraine. Cephalalgia 2006; 26: 1061-1070.
17. Cui M Khanijou S Rubino J Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.
18. Dodick DW Turkel CC DeGryse RE Aurora SK Silberstein SD Lipton RB et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936.
19. Gobel H Heinze A Heinze-Kuhn K Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001; 91: 195-199.
20. Truong D Brodsky M Lew M Brashear A Jankovic J Molho E et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16: 316-323.
21. Dowson AJ Kilminster SG Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D 2008; 9: 147-158.
22. Hobson DE Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache 1997; 37: 253-255.
23. Smuts J Barnard P. Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 2000; 20: 332-332.
24. Freund BJ Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache 2000; 40: 231-236.
25. Martelletti P van Suijlekom H. Cervicogenic headache: practical approaches to therapy. CNS Drugs 2004; 18: 793-805.
26. Sjaastad O Fredriksen TA Pfaffenrath V. Cervicogenic headache: diagnostic criteria. The Cervicogenic Headache International Study Group. Headache 1998; 38: 442-445.
27. Stovner LJ Kolstad F Helde G. Radiofrequency denervation of facet joints C2-C6 in cervicogenic headache: a randomized, double-blind, sham-controlled study. Cephalalgia 2004; 24: 821-830.
28. Bovim G Sand T. Cervicogenic headache, migraine without aura and tension-type headache. Diagnostic blockade of greater occipital and supra-orbital nerves. Pain 1992; 51: 43-48.
29. Zwart JA. Neck mobility in different headache disorders. Headache 1997; 37: 6-11.
30. Sand T Zwart JA Helde G Bovim G. The reproducibility of cephalic pain pressure thresholds in control subjects and headache patients. Cephalalgia 1997; 17: 748-755.
31. Mills E Chan A-W Wu P Vail A Guyatt G Altman D. Design, analysis and presentation of crossover trials. Trials 2009; 10: 27-27.
32. Diener HC Schorn CF Bingel U Dodick DW. The importance of placebo in headache research. Cephalalgia 2008; 28: 1003-1011.
33. Bovim G. Cervicogenic headache, migraine, and tension-type headache. Pressure-pain threshold measurements. Pain 1992; 51: 169-173.
34. Aurora S Dodick D Turkel C Degryse R Silberstein S Lipton R et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803.
35. Welch M Purkiss J Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-258.
36. Frese A Evers S. Biological markers of cervicogenic headache. Cephalalgia 2008; 28 (Suppl 1): 21-23.
37. Evers S. Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache. Neuropsychiatr Dis Treat 2007; 3: 761-764.
38. Zwart JA Bovim G Sand T Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 1994; 34: 458-462.
39. Jull G Amiri M Bullock-Saxton J Darnell R Lander C. Cervical musculoskeletal impairment in frequent intermittent headache. Part 1: Subjects with single headaches. Cephalalgia 2007; 27: 793-802.
40. Watson DH Trott PH. Cervical headache: an investigation of natural head posture and upper cervical flexor muscle performance. Cephalalgia 1993; 13: 272-284. discussion 32.
41. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005; 21: 433-438.
42. Headache Classification Subcommittee of the International Headache Society. The International Classification of headache disorders. Cephalalgia 2004; 24 (Suppl 1): 1-160.
43. Tobin J Flitman S. Occipital nerve blocks: when and what to inject? Headache 2009; 49: 1521-1533.
44. Vincent MB. Cervicogenic headache: a review comparison with migraine, tension-type headache, and whiplash. Curr Pain Headache Rep 2010; 14: 238-243.
45. Sjaastad O Fredriksen TA Pfaffenrath V. Cervicogenic headache: diagnostic criteria. Headache 1990; 30: 725-726.
46. Sjaastad O. Cervicogenic headache: comparison with migraine without aura; Vaga study. Cephalalgia 2008; 28 (Suppl 1): 18-20.
47. van Suijlekom JA Weber WE van Kleef M. Cervicogenic headache: techniques of diagnostic nerve blocks. Clin Exp Rheumatol 2000; 18 (2 Suppl 19): S39-S44.
48. Ashkenazi A Blumenfeld A Napchan U Narouze S Grosberg B Nett R et al. Peripheral nerve blocks and trigger point injections in headache management-a systematic review and suggestions for future research. Headache 2010; 50: 943-952.
49. Bovim G Berg R Dale LG. Cervicogenic headache: anesthetic blockades of cervical nerves (C2-C5) and facet joint (C2/C3). Pain 1992; 49: 315-320.
50. Fredriksen TA Hovdal H Sjaastad O. "Cervicogenic headache": clinical manifestation. Cephalalgia 1987; 7: 147-160.
51. Vincent MB. Is a de novo whiplash-associated pain most commonly cervicogenic headache? Cephalalgia 2008; 28 (Suppl 1): 32-34.
52. Stovner LJ Obelieniene D. Whiplash headache is transitory worsening of a pre-existing primary headache. Cephalalgia 2008; 28 (Suppl 1): 28-31.
53. Wheeler A. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998; 38: 468-471.
54. Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004; 7: 377-387.
55. Brin MF Lew MF Adler CH Comella CL Factor SA Jankovic J et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.